Human Umbilical Cord-derived Mesenchymal Stem Cells With Injectable Collagen Scaffold Transplantation for Chronic Ischemic Cardiomyopathy
Primary Purpose
Chronic Ischemic Cardiomyopathy
Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
hUC-MSCs+Injectable collagen scaffold+CABG
hUC-MSCs+CABG
CABG
Sponsored by
About this trial
This is an interventional treatment trial for Chronic Ischemic Cardiomyopathy
Eligibility Criteria
Inclusion Criteria:
- Male or female, 35-65 years old.
- Chronic coronary artery disease with coronary Stenosis detectable by percutaneous coronary intervention (PCI). Ineligibility for percutaneous revascularization, as assessed by coronary arteriography. Ineligibility for percutaneous revascularization procedures was determined by 2 expert committees: a surgical committee comprising 2 cardiovascular surgeons and a noninvasive cardiologist, and an interventional committee comprising 2 interventional cardiologists and 1 noninvasive cardiologist.
- MRI confirmed that chronic coronary artery disease and ischemic regions.
- Left ventricular ejection fraction (LVEF)≤40%.
- NYHA Class II-IV.
- No organ dysfunction for lung, liver and kidney.
- Patients are able and willing to observe therapeutic effect and adverse events.
- Signed informed consent.
- Negative serum pregnancy test.
- No coagulation dysfunction.
- Glycated hemoglobin ≤6.5.
Exclusion Criteria:
- Lactating or pregnant woman.
- Ineligibility for CABG.
- Unexplainable baseline laboratory abnormalities.
- Sensitivity to any of the study medications.
- Acute myocardial infarction within 1 months of enrollment in the study.
- Patients suffering cardiovascular disease, such as aortic disease, malignant arrhythmias, congenital heart disease, intracardiac mass, moderate or severe valvular stenosis or regurgitation.
- History of life threatening allergic or immune-mediated reaction.
- Systemic infection or severe local infection.
- Shock or MODS or patients cannot cooperate with doctors.
- Severe heart, lung, liver or renal dysfunction.
- Taking medicine that might have effect on outcomes assess.
- Suffering HIV, Hepatitis B or Hepatitis C.
- Participation in any clinical trial in recent three months.
- History of mental illness or suicide risk.
- High expectation or unrealistic demands.
- Recently suffered a lot of radiation exposure.
- Previous or current history of neoplasia or other comorbidity that could impact the patient's short-term survival.
- Patients with serious complications of coronary artery disease (e.g., perforation of interventricular septum and ventricular aneurysm and mitral regurgitation due to papillary muscle dysfunction).
- Abnormal coagulation function.
- Patients with hemodynamic instability which may lead to serious complications.
- Any condition that, in the judgment of the investigator, would place the patient at under risk.
Sites / Locations
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Active Comparator
Arm Label
hUC-MSCs+Injectable collagen scaffold+CABG
hUC-MSCs+CABG
CABG
Arm Description
Outcomes
Primary Outcome Measures
Incidence of treatment-emergent adverse events
Adverse events (AEs), serious adverse events (SAEs) and changes in vital signs, electrocardiogram (ECG) and laboratory values were measured.
Secondary Outcome Measures
Myocardial blood flow
Change in myocardial blood flow evaluated by Cardiac magnetic resonance imaging (MRI).
Left ventricle ejection fraction (LVEF)
Change in LVEF as measured by ultrasonic cardiogram (UCG) and Cardiac magnetic resonance imaging (MRI).
Infarct size
Change in infarct size evaluated by Cardiac magnetic resonance imaging (MRI).
New York Heart Association (NYHA) Functional Classification
Change in clinical symptoms evaluated by NYHA.
Canadian Cardiovascular Society (CCS) Angina Grading Scale
Change in clinical symptoms evaluated by CCS.
Full Information
NCT ID
NCT02635464
First Posted
December 13, 2015
Last Updated
December 21, 2020
Sponsor
Chinese Academy of Sciences
Collaborators
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
1. Study Identification
Unique Protocol Identification Number
NCT02635464
Brief Title
Human Umbilical Cord-derived Mesenchymal Stem Cells With Injectable Collagen Scaffold Transplantation for Chronic Ischemic Cardiomyopathy
Official Title
The Safety and Efficacy Assessment of Human Umbilical Cord-derived Mesenchymal Stem Cells (hUC-MSCs) With Injectable Collagen Scaffold Transplantation for Chronic Ischemic Cardiomyopathy
Study Type
Interventional
2. Study Status
Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
October 2015 (undefined)
Primary Completion Date
August 2019 (Actual)
Study Completion Date
August 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese Academy of Sciences
Collaborators
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study is designed to assess the safety and efficacy of allogeneic human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) with injectable collagen scaffold transplanted into patients with chronic ischemic cardiomyopathy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Ischemic Cardiomyopathy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
hUC-MSCs+Injectable collagen scaffold+CABG
Arm Type
Experimental
Arm Title
hUC-MSCs+CABG
Arm Type
Active Comparator
Arm Title
CABG
Arm Type
Active Comparator
Intervention Type
Biological
Intervention Name(s)
hUC-MSCs+Injectable collagen scaffold+CABG
Intervention Description
Patients underwent Coronary Artery Bypass Surgery (CABG) with 10^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) in collagen scaffold injecting in the infarct region.
Intervention Type
Biological
Intervention Name(s)
hUC-MSCs+CABG
Intervention Description
Patients underwent Coronary Artery Bypass Surgery (CABG) with 10^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) injecting in the infarct region.
Intervention Type
Procedure
Intervention Name(s)
CABG
Intervention Description
Patients underwent CABG alone.
Primary Outcome Measure Information:
Title
Incidence of treatment-emergent adverse events
Description
Adverse events (AEs), serious adverse events (SAEs) and changes in vital signs, electrocardiogram (ECG) and laboratory values were measured.
Time Frame
up to 24 months after surgery
Secondary Outcome Measure Information:
Title
Myocardial blood flow
Description
Change in myocardial blood flow evaluated by Cardiac magnetic resonance imaging (MRI).
Time Frame
1, 3, 6, 12 and 24 months
Title
Left ventricle ejection fraction (LVEF)
Description
Change in LVEF as measured by ultrasonic cardiogram (UCG) and Cardiac magnetic resonance imaging (MRI).
Time Frame
1, 3, 6, 12 and 24 months
Title
Infarct size
Description
Change in infarct size evaluated by Cardiac magnetic resonance imaging (MRI).
Time Frame
1, 3, 6, 12 and 24 months
Title
New York Heart Association (NYHA) Functional Classification
Description
Change in clinical symptoms evaluated by NYHA.
Time Frame
1, 3, 6, 12 and 24 months
Title
Canadian Cardiovascular Society (CCS) Angina Grading Scale
Description
Change in clinical symptoms evaluated by CCS.
Time Frame
1, 3, 6, 12 and 24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female, 35-65 years old.
Chronic coronary artery disease with coronary Stenosis detectable by percutaneous coronary intervention (PCI). Ineligibility for percutaneous revascularization, as assessed by coronary arteriography. Ineligibility for percutaneous revascularization procedures was determined by 2 expert committees: a surgical committee comprising 2 cardiovascular surgeons and a noninvasive cardiologist, and an interventional committee comprising 2 interventional cardiologists and 1 noninvasive cardiologist.
MRI confirmed that chronic coronary artery disease and ischemic regions.
Left ventricular ejection fraction (LVEF)≤40%.
NYHA Class II-IV.
No organ dysfunction for lung, liver and kidney.
Patients are able and willing to observe therapeutic effect and adverse events.
Signed informed consent.
Negative serum pregnancy test.
No coagulation dysfunction.
Glycated hemoglobin ≤6.5.
Exclusion Criteria:
Lactating or pregnant woman.
Ineligibility for CABG.
Unexplainable baseline laboratory abnormalities.
Sensitivity to any of the study medications.
Acute myocardial infarction within 1 months of enrollment in the study.
Patients suffering cardiovascular disease, such as aortic disease, malignant arrhythmias, congenital heart disease, intracardiac mass, moderate or severe valvular stenosis or regurgitation.
History of life threatening allergic or immune-mediated reaction.
Systemic infection or severe local infection.
Shock or MODS or patients cannot cooperate with doctors.
Severe heart, lung, liver or renal dysfunction.
Taking medicine that might have effect on outcomes assess.
Suffering HIV, Hepatitis B or Hepatitis C.
Participation in any clinical trial in recent three months.
History of mental illness or suicide risk.
High expectation or unrealistic demands.
Recently suffered a lot of radiation exposure.
Previous or current history of neoplasia or other comorbidity that could impact the patient's short-term survival.
Patients with serious complications of coronary artery disease (e.g., perforation of interventricular septum and ventricular aneurysm and mitral regurgitation due to papillary muscle dysfunction).
Abnormal coagulation function.
Patients with hemodynamic instability which may lead to serious complications.
Any condition that, in the judgment of the investigator, would place the patient at under risk.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jianwu Dai, Ph.D.
Organizational Affiliation
Chinese Academy of Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210008
Country
China
12. IPD Sharing Statement
Citations:
PubMed Identifier
32910197
Citation
He X, Wang Q, Zhao Y, Zhang H, Wang B, Pan J, Li J, Yu H, Wang L, Dai J, Wang D. Effect of Intramyocardial Grafting Collagen Scaffold With Mesenchymal Stromal Cells in Patients With Chronic Ischemic Heart Disease: A Randomized Clinical Trial. JAMA Netw Open. 2020 Sep 1;3(9):e2016236. doi: 10.1001/jamanetworkopen.2020.16236.
Results Reference
derived
Learn more about this trial
Human Umbilical Cord-derived Mesenchymal Stem Cells With Injectable Collagen Scaffold Transplantation for Chronic Ischemic Cardiomyopathy
We'll reach out to this number within 24 hrs